Meso Scale Discovery Launches New Quickplex™ SQ 120 Multiplex Immunoassay Instrument
Rockville, Maryland (PRWEB) July 17, 2013 -- “We are very excited about the launch of the QuickPlex instrument,” said Jacob Wohlstadter, President and CEO. “The QuickPlex demonstrates our commitment to serving the full spectrum of the life science and clinical research community with unsurpassed immunoassay performance. It is not only affordable, but was developed under design control and validated through MSD’s quality management system.”
“This instrument really represents the next generation of high-performance multiplex systems. It is smaller, faster and costs less to operate than our previous instruments, yet still offers significant performance advantages such as our new single-well read mode,” said Dr. James Wilbur, General Manager. “We’re particularly excited about our special academic pricing, which fulfills our longstanding goal of making MSD technology accessible to researchers at universities and other teaching institutions.”
Based on MSD’s proprietary MULTI-ARRAY® technology, the QuickPlex complements MSD’s SECTOR® line of instruments, through which MSD has established itself as a leader in highly-sensitive, multiplexed immunoassays. The QuickPlex is fully compatible with the large menu of commercially available assays and components developed for the SECTOR product line, including MSD’s new validated biomarker kits.
For more information on QuickPlex, call Customer Service at 1-301-2085 or 1-240-632-5885; email customerservice(at)mesoscale(dot)com; or visit http://www.mesoscale.com/QuickPlex.
About Meso Scale Diagnostics, LLC.
Meso Scale Diagnostics, LLC., based in Rockville, Maryland, develops, manufactures, and markets instruments and assays for array-based biological measurements for research use in life sciences and for biodefense applications. More information about MSD and its products can be found at http://www.mesoscale.com.
Jonathan Klein-Evans, Meso Scale Discovery, http://www.mesoscale.com, 1-240-314-2600, [email protected]
Share this article